Y-mabs receives priority review status for cancer drug in China

A potential launch of Y-mabs's drug Danyelza is one step closer after being granted priority review status, ensuring a faster assessment by the Chinese authorities.

Photo: Thomas Peter/Reuters/Ritzau Scanpix

In a collaboration with the partner Schiclone Pharmaceuticals, biopharmaceutical company Y-mabs has been granted priority review by China's National Medical Products Administration (NMPA).

The drug Danyelza, which has received the special status, is for the treatment of neuroblastoma in the bone or bone marrow. The cancer develops in nerve tissue in infants and children. In the US, the drug was approved and fast-tracked by the FDA under the accelerated approval program.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs